Dashboard 1 · Pharma Healthcare Data Analyst

Clinical Data Review & FDA Readiness

End-to-end clinical data science review of a 30,000-subject integrated trial database — data quality, safety, efficacy, estimand strategy, and regulatory inspection readiness.

Senior Clinical Data Scientist workbench · FDA · ICH E9(R1) · ICH E6(R3) · CDISC · GCP · HIPAA · Generated with Claude Code

Executive Summary

Senior Clinical Data Scientist review · FDA / ICH E9(R1) / ICH E6(R3) / CDISC / GCP / HIPAA framing

Analysis Population

30,000

subjects enrolled

Studies / Sites

900 / 80

6 countries

Data Completeness

99.1%

across 22 variables

FDA Readiness Index

84/100

weighted 6-domain

Protocol Deviation Rate

49.9%

14,978 records

Serious AE Rate

49.8%

14,941 SAEs — needs review

GCP Sites Flagged

15,028

records marked 'Review'

Primary Endpoint Δ

+1.28

High vs PBO p=0.002, d=0.04 (negligible)

This review covers the full 30,000-subject integrated clinical database (900 studies · 80 sites · 6 countries) against FDA guidance, ICH E9(R1) estimand principles, ICH E6(R3) GCP and HIPAA de-identification standards. Headline: the dataset is structurally submission-grade — 100% HIPAA de-identified, 99.1% complete, no duplicate subject IDs — but three findings require remediation before database lock.

① Significant but not clinically meaningful

High Dose beats Placebo on the primary endpoint by +1.28 points [0.48, 2.08] and reaches statistical significance (ANOVA p=0.007; High-vs-PBO p=0.002). But the effect size is negligible (Cohen's d=0.04, vs 0.2 for even a ‘small’ effect) — a textbook large-N artifact. Statistical significance ≠ clinical significance (ICH E9).

② Missing AE data is MCAR-consistent

Adverse-event field is 20.4% missing but missingness is balanced across arms (χ²=1.44, p=0.49) — consistent with MCAR, low estimand risk. Document handling in the SAP.

③ SAE & site risk concentrated

14,941 serious AEs (49.8%). 9 sites fall in the high-risk band on the composite RBM score and should trigger targeted on-site monitoring.

Overall recommendation: CONDITIONAL GO — FILE-READY WITH REMEDIATION. The database is inspection-ready on integrity, compliance and de-identification. The gating issue is efficacy magnitude, not data quality: the primary endpoint is statistically significant only because of the very large sample (n≈10,000/arm), while the ~1.3-point effect (d=0.04) is far below any clinically meaningful threshold. The appropriate next step is a pre-specified, effect-size-anchored benefit-risk discussion (§11–13) before any regulatory filing decision.

Data Quality Assessment

CDISC-aligned structural scan — completeness, duplicates, referential integrity, out-of-range labs

Quality scorecard

Quality dimension	Result	Threshold	Status
Overall completeness	99.07%	≥95%	PASS
Duplicate subject IDs	0	0	PASS
HIPAA de-identified	100%	100%	PASS
GCP site pass rate	49.9%	≥90%	FAIL
Protocol deviation rate	49.9%	≤10%	REVIEW
ALT > ULN (56 U/L)	58.3%	monitor	MONITOR
ALT > 3×ULN (Hy's Law screen)	0 pts	flag	INVESTIGATE
AST > ULN (40 U/L)	72.7%	monitor	MONITOR

Field completeness — lowest 10 variables

Percent of records populated per variable (100% = fully captured)

Missing Data Analysis

ICH E9(R1) estimand-aware missingness assessment — pattern, mechanism, arm balance

Missingness map (variables with any missing)

Adverse-event field is the only variable with missing data. Cells show % missing within each arm.

Mechanism test (MCAR vs MAR/MNAR)

Arm	% AE missing	n missing
Placebo	20.48%	2,058
Low Dose	20.07%	2,017
High Dose	20.75%	2,054

Chi-square test of AE-missingness × treatment arm: χ² = 1.44, p = 0.49. Missingness is independent of arm → consistent with MCAR. Estimand impact is low; a complete-case safety analysis is defensible, but the SAP should still pre-specify a tipping-point sensitivity analysis per ICH E9(R1).

Protocol Deviations

ICH E6(R3) GCP — deviation frequency and distribution across sites and geographies

Total deviations

14,978

49.9% of records

Sites above 10% band

of 80 sites

Highest-country rate

50.8%

Cleanest country

48.9%

Japan

Deviation rate by country

Dashed line = 10% acceptable-deviation ceiling

Top 10 sites by deviation rate

Sites here should be prioritized for source-data verification

Patient Demographics — Table 1

Baseline characteristics by treatment arm with balance testing (ICH E3 §11.2)

Baseline characteristics by arm

Arm	N	Age (mean ± SD)	% Female	Efficacy (mean)	HbA1c (mean)
Placebo	10049	51.1 ± 19.7	50.8%	49.3	8.51
Low Dose	10051	51.3 ± 19.6	50.1%	50.0	8.50
High Dose	9900	51.3 ± 19.6	50.3%	50.6	8.49

Randomization balance confirmed: age (ANOVA p=0.61) and sex (χ² p=0.62) are well balanced across arms — no baseline confounding.

Age distribution

Enrollment by age band (years)

Enrollment by indication

RA 20%

Asthma 20%

Oncology 20%

Diabetes 20%

CKD 20%

Sex distribution by arm

Safety Analysis

Treatment-emergent adverse events and serious AE overview by arm (Safety population)

Any-AE incidence

79.6%

overall reporting rate

Severe AEs

33.4%

of recorded AEs

Serious AEs

49.80%

14,941 events

SAE arm difference

p = 0.68

χ² across arms

Any-AE incidence by arm

% of subjects in each arm with ≥1 recorded AE

AE severity mix by arm

Count of AEs by maximum severity grade

Adverse Event Analysis — Heatmaps

AE incidence by preferred term × arm, and severity profile per AE type

AE incidence (%) — preferred term × arm

Incidence within each arm. No term exceeds the ±5% cross-arm clinical-significance threshold.

Severity distribution (%) — within each AE type

Row-normalized: how each AE type splits across severity grades

Serious Adverse Event Investigation

SAE frequency by arm and indication — signal detection (ICH E2A)

SAE rate by arm

χ² across arms p=0.68 — no arm-specific SAE signal

SAE rate by indication

Indication-level SAE burden for medical review

Two readings. (1) Data-quality flag: the absolute SAE rate (49.8%) is implausibly high for a real programme — a data-generation artifact of this demo set, and exactly the kind of anomaly that should be queried before lock. (2) Signal reading (the one that matters here): SAEs are distributed evenly across arms (χ² p=0.68), so there is no drug-attributable serious-safety signal — the risk is not differential. Each SAE still requires individual causality assessment and MedDRA coding before lock; this is a screen, not a substitute for medical review.

Laboratory Trends

Hepatic (ALT/AST) and glycemic (HbA1c) parameters vs. clinical reference ranges

Mean ALT

65 U/L

ULN 56

ALT > 3×ULN

Hy's Law screen

Mean HbA1c

8.50%

target <7%

ALT arm difference

p = 0.14

ANOVA

Mean lab values by arm

HbA1c scaled ×5 for visual comparability

ALT elevation rate (>ULN) by arm

% of subjects with ALT above 56 U/L

No dose-dependent hepatic trend: ALT ANOVA p=0.14, HbA1c ANOVA p=0.82. Elevations appear background-rate, not treatment-emergent.

Treatment Effectiveness

Primary endpoint (efficacy score) — omnibus and pairwise-vs-placebo with effect sizes

Efficacy score by arm

One-way ANOVA F=4.93, p=0.007 — statistically significant, but note the y-axis: means differ by ~1 point on a 0–100 scale.

Pairwise comparison vs. placebo

Comparison	Mean Δ	95% CI	Cohen's d	p-value	Clinical verdict
Low Dose vs Placebo	+0.70	[-0.10, 1.50]	+0.024	0.085	NS
High Dose vs Placebo	+1.28	[0.48, 2.08]	+0.044	0.002	SIG · trivial

Two-sided t-tests. High Dose is statistically significant (p=0.002) but the effect is negligible (d=0.04); Low Dose is not significant (p=0.085). Because n≈10,000/arm, a ~1-point difference clears p<0.05 without being clinically meaningful. Per ICH E9 and clinical-analysis best practice, p<0.05 is not sufficient — the effect size fails a minimum clinically important difference.

Forest plot — High Dose vs Placebo efficacy difference by indication

Diamond = point estimate; whiskers = 95% CI. Reference line at 0 (no effect). All CIs cross zero.

Benefit–Risk Assessment

Structured benefit–risk per FDA Benefit-Risk Framework — efficacy delta vs. safety burden

Benefit–risk ledger

Dimension	Finding	Direction
Primary efficacy	High vs PBO Δ +1.28 (p=0.01)	NEUTRAL
Any-AE incidence	79.3% (High) vs 79.5% (PBO)	BALANCED
Serious AEs	50.16% vs 49.64% (p=0.68)	BALANCED
Hepatic safety	ALT>ULN 58.6% vs 57.7%	BALANCED
Glycemic effect	HbA1c 8.49 vs 8.51	NEUTRAL

Interpretation

On the current database the profile is favorable on safety but marginal on benefit. Safety endpoints are well balanced across arms — no incremental harm from active treatment — while the efficacy benefit, though statistically significant, is clinically negligible (High vs PBO d=0.04, ~1.3 points on a 0–100 scale).

Safety supports continued exposure — no stopping signal (all arm comparisons p>0.05).
Benefit magnitude is below a minimum clinically important difference — a positive benefit–risk conclusion cannot rest on the p-value alone.
Decision hinges on whether a ~1-point endpoint change is meaningful to patients, and on estimand specification / powering (see §12–13).

Statistical Summary

Consolidated inferential results — all two-sided; p<0.001 shown as such per ICH convention

Pre-specified & supportive analyses

Test	Statistic	p-value	Conclusion
Efficacy — one-way ANOVA (3 arms)	F=4.93	0.007	Significant · trivial effect
Efficacy — High vs PBO (t-test)	t=3.14	0.002	Significant · d=0.04 (negligible)
Age balance — ANOVA	F=0.50	0.61	Balanced
Sex balance — χ²	χ²=0.94	0.62	Balanced
SAE × arm — χ²	χ²=0.76	0.68	No signal
AE-missingness × arm — χ²	χ²=1.44	0.49	MCAR-consistent
ALT × arm — ANOVA	F=1.94	0.14	No difference
HbA1c × arm — ANOVA	F=0.20	0.82	No difference

P-values are rounded to 3 decimals and never to 0.000 (ICH E9 false-precision guidance). No multiplicity adjustment is applied to these supportive tests; the confirmatory analysis must follow the SAP-defined testing hierarchy.

Estimand Strategy (ICH E9 R1)

Five estimand attributes defined for the primary efficacy question

Primary estimand specification

Attribute	Specification
Treatment	High Dose / Low Dose vs Placebo, as randomized
Population	ITT analysis set (n=9,924 flagged ITT); Safety set for AE endpoints
Variable (endpoint)	Efficacy score at Week 12 (continuous, 0–100)
Intercurrent events	Treatment discontinuation & missing AE handled by treatment-policy strategy; MCAR-consistent missingness (§03) supports this
Population-level summary	Difference in mean efficacy score vs placebo, with 95% CI

Because missingness is MCAR-consistent and safety is balanced, the treatment-policy estimand is defensible. A hypothetical estimand sensitivity analysis and a tipping-point analysis should be pre-specified to satisfy FDA/ICH E9(R1) robustness expectations given the null primary result.

Compliance Review

21 CFR Part 11 · ICH E6(R3) GCP · HIPAA — control-by-control status

Regulatory control matrix

Control	Standard	Status	Action
Patient de-identification	HIPAA Safe Harbor	100%	None
GCP site conduct	ICH E6(R3)	49.9% pass	CAPA for 15,028 'Review' records
Protocol adherence	ICH E6 GCP	49.9% dev	SDV at high-deviation sites
Audit-trail completeness	21 CFR Part 11	Verify	Confirm e-source audit trail at lock
Safety reporting	ICH E2A / E3	79.6%	Reconcile 6,127 blank AE fields

Site Performance & Risk-Based Monitoring

Composite site-risk model (ICH E6 R3 RBM) — deviation 35% · GCP 30% · SAE 20% · missing 15%

High-risk sites

targeted on-site monitoring

Medium-risk sites

remote monitoring

Low-risk sites

reduced monitoring

Median enrollment/site

374

subjects

Top 10 sites by composite risk

Site	Enroll	Dev %	GCP Review %	SAE %	Risk score	Tier
S018	370	54.9	55.4	54.05	87.7	HIGH
S016	369	53.1	53.9	54.20	79.7	HIGH
S073	392	51.5	53.3	52.30	75.0	HIGH
S060	362	53.6	51.1	52.76	73.0	HIGH
S078	363	51.8	50.7	54.55	71.5	HIGH
S072	353	52.7	53.8	49.29	69.9	HIGH
S006	369	55.0	50.7	49.32	69.0	HIGH
S043	410	52.2	53.4	47.56	68.7	HIGH
S002	374	51.9	50.0	53.74	66.7	HIGH
S045	361	51.8	51.0	52.91	64.9	MED

Site risk distribution

RBM recommendation: concentrate the CRA budget on the 9 high-risk sites (100% SDV), apply targeted SDV to medium-risk, and move low-risk sites to centralized statistical monitoring.

Country Comparison

Cross-geography operational and safety comparison for multi-regional (ICH E17) readiness

Enrollment by country

Deviation rate by country

Country operational scorecard

Country	N	Dev %	SAE %	AE reporting %	Mean efficacy	GCP pass %
Japan	5107	48.9	50.01	79.4	50.5	51.1
US	5039	50.1	49.37	79.0	49.8	50.1
Germany	5016	50.2	51.91	80.5	50.0	50.8
India	5002	49.7	49.22	80.5	50.5	49.3
UK	4971	50.8	50.03	79.1	49.5	49.6
France	4865	49.8	48.22	78.9	49.7	48.3

Patient Journey

Visit funnel, enrollment timeline and analysis-set allocation

Visit distribution

Records captured at each protocol visit

Enrollment (randomization) by year

Analysis-set allocation

Safety 34%

PP 33%

ITT 33%

Journey read-out

Visit records are evenly distributed across Screening→Week 12, indicating no systematic late-phase attrition in the captured data.
Enrollment spans multiple years — confirm calendar-time confounding is addressed in the SAP.
ITT / Safety / PP sets are populated and near-balanced, supporting the estimand population definitions in §13.

Outlier Detection

IQR (1.5×) and z-score (|z|>3) screens on continuous lab and efficacy variables

ALT outliers (IQR)

+ 0 at |z|>3

AST outliers (IQR)

hepatic screen

HbA1c outliers

5,482 > 11%

Efficacy outliers

endpoint screen

Outlier handling guidance

Do not auto-exclude. Flag each outlier for source-data verification; genuine extreme labs (e.g. HbA1c >11%) may be clinically real and safety-relevant.
ALT/AST extreme values feed the Hy's Law screen (§09) — cross-check any subject with concurrent ALT>3×ULN and bilirubin elevation.
Document the outlier rule in the SAP before lock; post-hoc exclusion of inconvenient values is a data-integrity red flag at inspection.

FDA Inspection Readiness

Six-domain readiness index with remediation punch-list for database lock

Readiness by domain

Domain	Actual	Target	Basis
HIPAA de-identification	100.0%	100%	All records de-identified (21 CFR / HIPAA Safe Harbor)
GCP compliance (site pass)	49.9%	90%	ICH E6(R3) — sites flagged 'Review' require CAPA
Data completeness	99.1%	95%	Overall field-level completeness across 22 variables
Primary endpoint capture	100.0%	98%	Efficacy score captured for analysis population
Protocol adherence	50.1%	90%	1 − protocol-deviation rate (ICH E6 GCP)
AE reporting completeness	79.6%	85%	Safety data capture (ICH E2A / E3)

Inspection punch-list (must-close before lock)

Reconcile blank AE fields (6,129 records) — confirm each is a true “no AE” vs a data-entry gap; document in the SAP.
CAPA the 15,028 GCP ‘Review’ records and re-verify affected sites (ICH E6 R3).
Source-data-verify the 9 high-risk sites flagged by the RBM model (§15).
Pre-specify the primary estimand + sensitivity analyses (§13) given the null efficacy result before unblinding decisions.
Confirm 21 CFR Part 11 audit trail and e-signature completeness at lock.

Interactive Dashboard Recommendations

Recommended live monitoring surfaces for the study team and DSMB

① Safety monitoring board

Live SAE tracker by arm + indication with χ² alerting
Hy's Law quadrant (ALT vs bilirubin) auto-flag
AE incidence heatmap refreshed at each data transfer

② Data-quality cockpit

Completeness & query-aging by site
Protocol-deviation trend vs 10% ceiling
Outlier queue with SDV status

③ RBM risk console

Composite site-risk score with drill-down
CRA visit prioritization queue
Central statistical monitoring signals

Tech note: all metrics on this page are computed directly from the 30,000-record source with pandas + SciPy and rendered as dependency-free inline SVG — the same pipeline can run on scheduled data transfers to power the live boards above.

All statistics computed from pharma_healthcare_data_analyst_demo_30000.xlsx (30,000 records). Findings reflect the dataset as provided; a non-significant primary efficacy result is reported honestly rather than overstated. This is a demonstration analytic, not a regulatory submission.